A Phase IIa, Double-Blind, Randomised, Parallel-Group, Multi-Centre Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2012
At a glance
- Drugs AZD 2066 (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 31 Aug 2012 Results presented at the 14th World Congress on Pain.
- 28 Aug 2012 Primary endpoint 'Pain-intensity' has not been met, based on results presented at 14th World Congress on Pain.
- 28 Aug 2012 Primary endpoint 'Numerical-Rating-Scale' has not been met, based on results presented at 14th World Congress on Pain
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History